There is great interest in developing new non-invasive ways to determine which women with an abnormal mammogram should have a biopsy, especially with tests done on a blood sample. Blood tests like the one we are studying could help reduce the number of women advised to undergo additional procedures such as ultrasound, MRI, or even biopsy itself.

Mammography has been proven to decrease mortality from breast cancer. However, there are false positives which result in women having additional imaging tests and/or a breast biopsy to be sure the abnormality seen on imaging isn’t breast cancer.

Although this study does not change any care recommendations throughout the patient’s current treatment, it does have the potential to help women in the future get easier, less-invasive, more accurate breast cancer detection. This study aims to provide sufficient samples to demonstrate its efficacy in meeting or exceeding biopsy results.

Interested in a research studyvto see if an investigational vaccine could help protect your baby?

Boeson Research is currently enrolling expectant mothers in a vaccine trial to provide protection against RSV in their newborns.

RSV is an important cause of morbidity and mortality worldwide, with a substantial burden of disease borne by young infants. Rates of severe RSV illness are highest in infants <6 months of age, with a peak in hospitalization between 1 and 2 months of life, though the highest case-fatality rates are observed in the neonatal period (<1 month). Infants born prematurely and those with underlying cardiac or pulmonary disease are at further increased risk of severe clinical disease due to RSV.

No specific treatments for RSV exist, and available prophylactic measures (ie, RSV monoclonal antibody) are limited to use in only those infants at highest risk; additionally, use of available RSV prophylaxis can be cost-prohibitive. While active immunization against RSV in infants might be ideal, multiple efforts, extending over half a century, to develop a safe and effective RSV vaccine to protect infants from disease have yielded little success. The early peak of disease presents a further obstacle to an active vaccination strategy for infants. Given these challenges, maternal immunization to protect infants early in life offers an attractive strategy for infant disease prevention.

The RSV vaccine is being developed to prevent medically significant RSV-associated lower respiratory tract infections (LRTI) in infants by active immunization of pregnant women.